|
[Table of
Contents]
|
|
Volume: 22S1 • April 1996
Guidelines for Preventing the
Transmission of Tuberculosis in Canadian Health Care
Facilities and Other Institutional Settings
Doses of and common adverse reactions to
first-line antituberculous drugs (level 1 evidence)
(96)
|
Drug
|
Daily dose in
adults (and children), mg/kg
|
Usual daily
dose in mg
|
Twice weekly
dose in mg
|
Adverse reactions*
(comments)
|
|
Isoniazid1
|
5
(10-20)
|
300
|
900-1200
|
Hepatitis,paresthesia
|
|
Rifampin
|
10
(10-20)
|
600
|
600
|
Hepatitis,flu-like illness (reduced effect of
certain other drugs)
|
|
Pyrazinamide
|
15-30
(15-30)
|
1500
|
2500
|
Hepatitis,elevated serum uric acid level,
arthralgia
|
|
EthambutolÞ
|
15-25
|
800-1200
|
2400
|
Retrobulbar neuritis
|
|
StreptomycinÞ
|
15
(20-40)
|
1000
|
1000
|
Vertigo, tinnitus, renal failure
|
|
Vitamin B6
|
|
|
25
|
Optional
|
|
* All drugs may cause rash, nausea and
fever.
1 Maximum 300 mg per day for adults
and children.
Þ Dose may need to be adjusted if renal
failure occurs, maximum 2.5 gm/day.
|
These drugs have maximum doses, whether administered
in daily, twice weekly, or thrice weekly regimens
(see Table 2, Am J Respir Crit Care Med
1994;149:159-74).
[Previous] [Table of Contents] [Next]
|
